

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number
WO 03/087102 A1

- (51) International Patent Classification⁷: **C07D 491/22**, A61K 31/438, 31/439, A61P 25/00
- (74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; Astrazeneca AB, S-151 85 Södertälje (SE).
- (21) International Application Number: PCT/SE03/00613
- (22) International Filing Date: 15 April 2003 (15.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0201186-4 18 April 2002 (18.04.2002) SE
0203607-7 4 December 2002 (04.12.2002) SE
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **CHANG, Hui-Fang** [—/US]; Astrazeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **LI, Yan** [US/US]; Astrazeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **PHILLIPS, Eifion** [GB/US]; Astrazeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US).
- Published:**
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: FURYL COMPOUNDS



(57) Abstract: Compounds of formula (I) and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.



WO 03/087102 A1

FURYL COMPOUNDS

TECHNICAL FIELD

This invention relates to novel spiroazabicyclic heterocyclic amines or
 5 pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy.


BACKGROUND OF THE INVENTION

The use of compounds which bind to nicotinic acetylcholine receptors for the treatment of a range of disorders involving reduced cholinergic function such as Alzheimer's
 10 disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease is discussed in McDonald *et al.*, (1995) "Nicotinic Acetylcholine Receptors: Molecular Biology, Chemistry and Pharmacology", Chapter 5 in Annual Reports in Medicinal Chemistry, vol. 30, pp. 41-50, Academic Press Inc., San Diego, CA; and in Williams *et al.*, (1994) "Neuronal
 15 Nicotinic Acetylcholine Receptors," Drug News & Perspectives, vol. 7, pp. 205-223.

DESCRIPTION OF THE INVENTION

This invention comprises compounds that are potent ligands for nicotinic acetylcholine receptors (nAChR's).

Compounds of the invention are those in accord with formula I:



I

and pharmaceutically-acceptable salts thereof, wherein:

Ar is selected from a 2-, or 3-linked furyl, benzofuryl or isobenzofuryl; substituted with 1, 2 or 3 substituents, or, when a benzofuryl or isobenzofuryl with 0, 1, 2, or 3
 25 substituents, independently selected at each occurrence from C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ halogenated alkyl, C₁₋₄ oxygenated alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, halogen, -CO₂R¹, -C(O)R¹, -CN, -NO₂, -(CH₂)_nNR¹R²;

n is 0, 1, or 2;

R¹ and R² are independently selected at each occurrence from hydrogen or C₁₋₄ alkyl;

R is a substituent selected from hydrogen, C₁₋₄alkyl, C₁₋₄ halogenated alkyl, C₁₋₄ oxygenated alkyl, or halogen.

Particular compounds of the invention are those wherein R is hydrogen and Ar is a 2-, or 3-linked furyl ring bearing a single substituent and said substituent is selected from methyl, ethyl, or halogen.

Other particular compounds of the invention are those wherein R is hydrogen and Ar is a 2-, or 3-linked benzofuryl ring which is unsubstituted or bears a single substituent, and said substituent is selected from methyl, ethyl, or halogen.

Particular compounds of the invention include:

- (2'R)-5'-(benzofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(2-bromofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-methylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-fluorofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-methylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-4-{spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carboxaldehyde;
(2'R)-5'-(5-hydroxymethylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-4-{spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carbonitrile;
(2'R)-5-{spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carbonitrile;
(2'R)-5'-(benzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(2-fluorobenzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine].

Other particular compounds of the invention include:

- (2'R)-5'-(5-fluorofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-chlorofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-bromofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-trifluoromethylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-aminomethylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-chlorofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-bromofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];
(2'R)-5'-(5-trifluoromethylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-
b]pyridine];
5 (2'R)-5'-(5-aminomethylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-
b]pyridine];
(2'R)-5'-(2,3-dimethylfuran-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-
b]pyridine];
(2'R)-5'-(2,3-dimethylfuran-5-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-
10 b]pyridine].

In another aspect the invention relates to compounds according to formula I and their use in therapy and compositions containing them.

In a further aspect the invention relates to compounds according to formula I wherein one or more of the atoms is labelled with a radioisotope of the same element. In a particular
15 form of this aspect of the invention the compound of formula I is labelled with tritium

In a particular aspect the invention relates to the use of compounds according to formula I for the therapy of diseases mediated through the action of nicotinic acetylcholine receptors. A more particular aspect of the invention relates to the use of compounds of formula I for the therapy of diseases mediated through the action of α_7 nicotinic acetylcholine
20 receptors.

Another aspect of the invention relates to a pharmaceutical composition comprising a compound as described above, and a pharmaceutically-acceptable diluent or carrier.

Another aspect of the invention relates to the above pharmaceutical composition for use in the treatment of prophylaxis of human diseases or conditions in which activation of the
25 α_7 nicotinic receptor is beneficial.

Another aspect of the invention relates to the above pharmaceutical composition for use in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

Another aspect of the invention relates to the above pharmaceutical composition for use in the treatment or prophylaxis of Alzheimer's disease, learning deficit, cognition deficit,
30 attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic

synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis.

Another aspect of the invention relates to a use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which activation of the α_7 nicotinic receptor is beneficial.

Another aspect of the invention relates to a use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

Another aspect of the invention relates to the above use, wherein the condition or disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder.

Another aspect of the invention relates to the above use, wherein the disorder is anxiety, schizophrenia, or mania or manic depression.

Another aspect of the invention relates to the above use, wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.

Another aspect of the invention relates to the use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis.

Another aspect of the invention relates to a method of treatment or prophylaxis of human diseases or conditions in which activation of the α_7 nicotinic receptor is beneficial which comprises administering a therapeutically effective amount of a compound as described above.

Another aspect of the invention relates to a method of treatment or prophylaxis of psychotic disorders or intellectual impairment disorders, which comprises administering a therapeutically effective amount of a compound as described above.

Another aspect of the invention relates to the above method, wherein the disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, or Attention Deficit Hyperactivity Disorder.

Another aspect of the invention relates to the above method, wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.

Another aspect of the invention relates to the above method, wherein the disorder is anxiety, schizophrenia or mania or manic depression.

Another aspect of the invention relates to a method of treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction, craving, pain, and for ulcerative colitis, which comprises administering a therapeutically effective amount of a compound as described above.

A further aspect of the invention relates to a pharmaceutical composition for treating or preventing a condition or disorder as exemplified below arising from dysfunction of nicotinic acetylcholine receptor neurotransmission in a mammal, preferably a human, comprising an amount of a compound of formula I, an enantiomer thereof or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and an inert pharmaceutically acceptable carrier.

For the above-mentioned uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.1 mg to about 20 mg/kg of animal body weight. Such doses may be given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose is in the range of from 5 mg to 1,400 mg, more preferably from 10 mg to 100 mg, and unit dosage forms suitable for oral administration comprise from 2 mg to 1,400 mg of the compound admixed with a solid or liquid pharmaceutical carrier or diluent.

The compounds of formula I, or an enantiomer thereof, and pharmaceutically acceptable salts thereof, may be used on their own or in the form of appropriate medicinal preparations for enteral or parenteral administration. According to a further aspect of the invention, there is provided a pharmaceutical composition including preferably less than 80% and more preferably less than 50% by weight of a compound of the invention in admixture with an inert pharmaceutically acceptable diluent or carrier.

Examples of diluents and carriers are:

- for tablets and dragees: lactose, starch, talc, stearic acid;
- for capsules: tartaric acid or lactose;

- for injectable solutions: water, alcohols, glycerin, vegetable oils;
- for suppositories: natural or hardened oils or waxes.

There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients.

5 A further aspect of the invention is the use of a compound according to the invention, an enantiomer thereof or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of one of the below mentioned diseases or conditions; and a method of treatment or prophylaxis of one of the above mentioned diseases or conditions, which comprises administering a therapeutically effective amount of a
10 compound according to the invention, or an enantiomer thereof or a pharmaceutically acceptable salt thereof, to a patient.

Compounds according to the invention are agonists of nicotinic acetylcholine receptors. While not being limited by theory, it is believed that agonists of the $\alpha 7$ nAChR (nicotinic acetylcholine receptor) subtype should be useful in the treatment or prophylaxis of
15 psychotic disorders and intellectual impairment disorders, and have advantages over compounds which are or are also agonists of the $\alpha 4$ nAChR subtype. Therefore, compounds which are selective for the $\alpha 7$ nAChR subtype are preferred. The compounds of the invention are indicated as pharmaceuticals, in particular in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders. Examples of psychotic disorders include
20 schizophrenia, mania and manic depression, and anxiety. Examples of intellectual impairment disorders include Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, and Attention Deficit Hyperactivity Disorder. The compounds of the invention may also be useful as analgesics in the treatment of pain (including chronic pain) and in the treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome,
25 and neurodegenerative disorders in which there is loss of cholinergic synapses. The compounds may further be indicated for the treatment or prophylaxis of jetlag, for use in inducing the cessation of smoking, craving, and for the treatment or prophylaxis of nicotine addiction (including that resulting from exposure to products containing nicotine).

It is also believed that compounds according to the invention are useful in the
30 treatment and prophylaxis of ulcerative colitis.


As used herein, the term "C₁₋₄ alkyl" refers to a straight-chained, branched, or cyclic C₁₋₄alkyl group.

As used herein the term "C₁₋₄ halogenated alkyl" refers to a C₁₋₄alkyl group substituted with 1, 2, or 3 halogen atoms.

As used herein the term "C₁₋₄ oxygenated alkyl" refers to a C₁₋₄ hydroxyalkyl or C₁₋₄ alkoxyalkyl group.

5 Methods of Preparation

Methods which may be used for the synthesis of compounds of formula I include the method outlined in Scheme 1. Unless otherwise noted Ar and R in Scheme 1 are as defined above for Formula 1.



10 **Scheme 1**

Compounds of formula I may be prepared from compounds of formula II wherein X represents a halogen or OSO₂CF₃ substituent by reaction with an appropriate organometallic compound of formula III in the presence of a suitable organometallic catalyst and solvent. Suitable compounds of formula III include boronic acids, in which M represents B(OH)₂, boronic acid esters, in which M represents B(OY)₂, where Y represents a suitable acyclic or
 15 cyclic alkyl or aryl group, and organotin compounds, in which M represents a suitable trialkylstannyl group, for example trimethylstannyl or tri-n-butylstannyl. Suitable organometallic catalysts include palladium (0) complexes, for example tetrakis(triphenylphosphine)palladium(0) or a combination of
 20 tris(dibenzylideneacetone)dipalladium(0) and a suitable triarylphosphine or triarylsarsine ligand, for example triphenylphosphine, tri(o-tolyl)phosphine or triphenylarsine. Suitable solvents include inert ether solvents, for example 1,2-dimethoxyethane, tetrahydrofuran, or 1,4-dioxane, or alcohols, such as ethanol, or mixtures thereof. If the compound of formula III is a boronic acid, the presence of a suitable base in addition to the other reagents is preferred.
 25 Suitable bases include sodium carbonate, cesium carbonate, and barium hydroxide. The reaction is carried out at a temperature of 0-120 °C, and preferably at a temperature of 60-120 °C.


Certain compounds of formula II wherein X represents halogen may be prepared from compounds of formula II wherein X represents hydrogen by reaction with a suitable

halogenating agent in a suitable solvent. Suitable halogenating agents include bromine. Suitable solvents include acetic acid. The reaction is preferably performed at a temperature of 0-50 °C, and most preferably at a temperature of 0-25 °C. Compounds of formula II may be prepared by the methods described in application WO99/03859.

5 Compounds of formula II wherein X represents OSO_2CF_3 may be prepared from compounds of formula II wherein X represents OH by reaction with trifluoromethanesulfonic anhydride or other trifluoromethanesulfonylating agent in the presence of a base and a suitable solvent. Suitable bases include pyridine, and 2,6-di-*t*-butylpyridine. The reaction is preferably performed at a temperature of -78 to 120 °C, and most preferably at a temperature of -78 to
10 0 °C.

Compounds of formula III are commercially available, are described in the literature of synthetic organic chemistry, or may be prepared by methods known to one skilled in the art of synthetic organic chemistry. For example, compounds of formula III in which M represents $\text{B}(\text{OH})_2$ may be prepared from suitable aromatic compounds having hydrogen or halogen
15 groups, *via* conversion to the corresponding aryllithium or arylmagnesium compounds followed by reaction with trialkylborate and subsequent hydrolysis of the resulting borate ester. Similarly, suitable aromatic compounds having hydrogen or halogen groups may be converted to compounds of formula III in which M represents a trialkylstannyl group *via* conversion to the corresponding aryllithium or arylmagnesium compounds followed by
20 reaction with an appropriate trialkylstannyl halide. The formation of the aryllithium or arylmagnesium compound is performed in a suitable inert solvent, for example, tetrahydrofuran. Alternatively, suitable aromatic compounds having halogen or OSO_2CF_3 may be converted to compounds of formula III in which M represents $\text{B}(\text{OH})_2$ *via* reaction with bis(pinacolato)diboron and an organometallic catalyst, followed by hydrolysis of the
25 resulting borate ester, or to compounds of formula III in which M represents a trialkylstannyl group *via* reaction with the appropriate bis(trialkyltin) in the presence of a suitable organometallic catalyst. The reaction is performed in a suitable inert solvent, for example tetrahydrofuran, and suitable organometallic catalyst include, for example tetrakis(triphenylphosphine). The reaction is performed at a temperature of about 0 °C to
30 about 150 °C, preferably about 20 °C to about 100 °C. For typical procedures for effecting such conversions, see, for example, *Organic Syntheses*, 1963, Coll. Vol. 4, 68; *J. Org. Chem.* 1995, 60, 7508.

An alternative synthesis of compounds of formula I is outlined in Scheme 2. Unless otherwise noted Ar, R, M and X in Scheme 2 are as defined above for Scheme 1, and Ar and R are as defined in Formula I. The conditions for effecting the preparation described in Scheme 2 would be similar to those under which the preparations described in Scheme 1 would be performed with corresponding M and X groups.




Scheme 2

Compounds of formula IV in which M represents $\text{B}(\text{OH})_2$ may be prepared from compounds of formula II in which X is halogen, *via* conversion to the corresponding aryllithium or arylmagnesium compounds followed by reaction with trialkylborate and subsequent hydrolysis of the resulting borate ester. Similarly, compounds of formula IV in which M represents SnR^3_3 and R^3 represents a $\text{C}_1\text{-C}_6$ alkyl group may be prepared from compounds of formula II in which X is halogen, *via* conversion to the corresponding aryllithium or arylmagnesium compounds followed by reaction with an appropriate trialkylstannyl halide.

The formation of the aryllithium or arylmagnesium compound is performed in a suitable inert solvent, for example, tetrahydrofuran, and Alternatively, compounds of formula IV in which M represents $\text{B}(\text{OH})_2$ may be prepared from compounds of formula II in which X represents halogen or OSO_2CF_3 *via* reaction with bis(pinacolato)diboron and an organometallic catalyst, followed by hydrolysis of the resulting borate ester, and compounds of formula IV in which M represents SnR^3_3 and R^3 represents a $\text{C}_1\text{-C}_6$ alkyl group may be prepared from compounds of formula II in which X represents halogen or OSO_2CF_3 *via* reaction with the appropriate bis(trialkyltin) $\text{R}^3_3\text{SnSnR}^3_3$ in the presence of a suitable organometallic catalyst. The reaction is performed in a suitable inert solvent, for example tetrahydrofuran, and suitable organometallic catalyst include, for example tetrakis(triphenylphosphine). The reaction is performed at a temperature of about 0°C to about 150°C , preferably about 20°C to about 100°C . For typical procedures for effecting such conversions, see, for example, *Organic Syntheses*, **1963**, Coll. Vol. 4, 68; *J. Org. Chem.* **1995**, 60, 7508.

A further aspect of the invention therefore relates to intermediates. Such intermediates are useful in the synthesis of compounds of formula I, and other compounds that bind

nicotinic acetylcholine receptors. Particularly useful intermediates are compounds of formula IV below:



wherein:

5 M represents $B(OH)_2$, $B(OR^3)_2$ or SnR^3_3 ;

R is a substituent selected from hydrogen, C_{1-4} alkyl, C_{1-4} halogenated alkyl, C_{1-4} oxygenated alkyl, or halogen;

R^3 represents a C_1 - C_6 alkyl group.

Particular compounds that are useful intermediates include:

10 (2'R)-5'-trimethylstannyl-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine].

It will be appreciated by one skilled in the art that certain optional aromatic substituents in the compounds of the invention may be introduced by employing aromatic substitution reactions, or functional group transformations to modify an existing substituent, or a combination thereof. Such reactions may be effected either prior to or immediately
15 following the processes mentioned above, and are included as part of the process aspect of the invention. The reagents and reaction conditions for such procedures are known in the art. Specific examples of procedures which may be employed include, but are not limited to, electrophilic functionalisation of an aromatic ring, for example *via* nitration, halogenation, or acylation; transformation of a nitro group to an amino group, for example *via* reduction, such
20 as by catalytic hydrogenation; acylation, alkylation, sulfonylation of an amino or hydroxyl group; replacement of an amino group by another functional group *via* conversion to an intermediate diazonium salt followed by nucleophilic or free radical substitution of the diazonium salt; or replacement of a halogen by another functional group, for example *via* nucleophilic or organometallically-catalysed substitution reactions.

25 Where necessary, hydroxy, amino, or other reactive groups may be protected using a protecting group as described in the standard text "Protecting groups in Organic Synthesis", 3rd Edition (1999) by Greene and Wuts.

The above-described reactions, unless otherwise noted, are usually conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one
30 atmosphere).

Unless otherwise stated, the above-described reactions are conducted under an inert atmosphere, preferably under a nitrogen atmosphere.

The compounds of the invention and intermediates may be isolated from their reaction mixtures by standard techniques.

5 Acid addition salts of the compounds of formula I which may be mentioned include salts of mineral acids, for example the hydrochloride and hydrobromide salts; and salts formed with organic acids such as formate, acetate, maleate, benzoate, tartrate, and fumarate salts. Acid addition salts of compounds of formula I may be formed by reacting the free base or a salt, enantiomer or protected derivative thereof, with one or more equivalents of the
10 appropriate acid. The reaction may be carried out in a solvent or medium in which the salt is insoluble or in a solvent in which the salt is soluble, e.g., water, dioxane, ethanol, tetrahydrofuran or diethyl ether, or a mixture of solvents, which may be removed in vacuum or by freeze drying. The reaction may be a metathetical process or it may be carried out on an ion exchange resin.

15 The compounds of formula I and IV exist in tautomeric or enantiomeric forms, all of which are included within the scope of the invention. The various optical isomers may be isolated by separation of a racemic mixture of the compounds using conventional techniques, e.g. fractional crystallisation, or chiral HPLC. Alternatively the individual enantiomers may be made by reaction of the appropriate optically active starting materials under reaction
20 conditions which will not cause racemisation.

Pharmacology

The pharmacological activity of compounds of the invention may be measured using the tests set out below:

Test A - Assay for affinity at $\alpha 7$ nAChR subtype

25 [¹²⁵I]- α -Bungarotoxin (BTX) binding to rat hippocampal membranes. Rat hippocampi were homogenized in 20 volumes of cold homogenization buffer (HB: concentrations of constituents (mM): tris(hydroxymethyl)aminomethane 50; MgCl₂ 1; NaCl 120; KCl 5; pH 7.4). The homogenate was centrifuged for 5 minutes at 1000 g, the supernatant was saved and the pellet re-extracted. The pooled supernatants were centrifuged for 20 minutes at
30 12000 g, washed, and resuspended in HB. Membranes (30–80 μ g) were incubated with 5 nM [¹²⁵I] α -BTX, 1 mg/mL BSA (bovine serum albumin), test drug, and either 2 mM CaCl₂ or 0.5 mM EGTA [ethylene glycol-bis(β -aminoethylether)] for 2 hours at 21 °C, and then filtered

and washed 4 times over Whatman glass fibre filters (thickness C) using a Brandel cell harvester. Pretreating the filters for 3 hours with 1% (BSA/0.01% PEI (polyethyleneimine) in water was critical for low filter blanks (0.07% of total counts per minute). Nonspecific binding was described by 100 μ M (–)-nicotine, and specific binding was typically 75%.

5 **Test B - Assay for affinity to the α 4 nAChR subtype**

[3 H]-(–)-nicotine binding. Using a procedure modified from Martino-Barrows and Kellar (Mol Pharm (1987) 31:169-174), rat brain (cortex and hippocampus) was homogenized as in the [125 I] α -BTX binding assay, centrifuged for 20 minutes at 12,000 x g, washed twice, and then resuspended in HB containing 100 μ M diisopropyl fluorophosphate. After 20
10 minutes at 4 °C, membranes (approximately 0.5 mg) were incubated with 3 nM [3 H]-(–)-nicotine, test drug, 1 μ M atropine, and either 2 mM CaCl_2 or 0.5 mM EGTA for 1 h at 4 °C, and then filtered over Whatman glass fiber filters (thickness C) (pretreated for 1 h with 0.5% PEI) using a Brandel cell harvester. Nonspecific binding was described by 100 μ M carbachol, and specific binding was typically 84%.

15 **Binding data analysis for Tests A and B**

IC_{50} values and pseudo Hill coefficients (nH) were calculated using the non-linear curve-fitting program ALLFIT (DeLean A, Munson P J and Rodbard D (1977) Am. J. Physiol., 235:E97-E102). Saturation curves were fitted to a one site model, using the non-linear regression program ENZFITTER (Leatherbarrow, R.J. (1987)), yielding KD values of
20 1.67 and 1.70 nM for the [125 I] α -BTX and [3 H]-(–)-nicotine ligands respectively. K_i values were estimated using the general Cheng-Prusoff equation:

$$\text{K}_i - [\text{IC}_{50}] / ((2 + ([\text{ligand}] / [\text{KD}])^n) / (n - 1))$$

where a value of $n=1$ was used whenever $\text{nH} < 1.5$ and a value of $n=2$ was used when $\text{nH} \geq 1.5$. Samples were assayed in triplicate and were typically $\pm 5\%$. K_i values were determined using 6
25 or more drug concentrations. The compounds of the invention are compounds with binding affinities (K_i) of less than 1000 nM in either Test A or Test B, indicating that they are expected to have useful therapeutic activity.


The compounds of the invention have the advantage that they may be less toxic, be more efficacious, be longer acting, have a broader range of activity, be more potent, produce
30 fewer side effects, are more easily absorbed or have other useful pharmacological properties.

Examples

Commercial reagents were used without further purification. *n*-Butyllithium was used as a solution in hexane. Mass spectra were recorded using an HPLC-MS system employing an HP-1100 HPLC and a Micromass LCZ Mass Spectrometer using APCI as the ionisation technique, an an HPLC-MS system employing an HP-1100 HPLC and an HP-1100-series mass selective detector using APCI as the ionisation technique, or a GC-MS system employing an HP-6890 gas chromatograph and an HP-5973 mass selective detector employing electron impact ionisation, and are reported as *m/z* for the parent molecular ion. Room temperature refers to 20–25 °C. 5'-Bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and other precursors were prepared as described in international patent application WO 99/03859. Radiolabelled forms of compounds of the examples are useful in a screen for the discovery of novel medicinal compounds which bind to and modulate the activity, *via* agonism, partial agonism, or antagonism, of the $\alpha 7$ nicotinic acetylcholine receptor. Such radiolabelled compounds are synthesized either by incorporating radiolabelled starting materials or, in the case of tritium, exchange of hydrogen for tritium by known methods. Known methods include (1) electrophilic halogenation, followed by reduction of the halogen in the presence of a tritium source, for example, by hydrogenation with tritium gas in the presence of a palladium catalyst, or (2) exchange of hydrogen for tritium performed in the presence of tritium gas and a suitable organometallic (e.g. palladium) catalyst.

Preparation 1

(2'R)-5'-(Furan-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]




(2'R)-5'-Bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (0.70 g, 2.37 mmol), 3-furylboronic acid (0.39 g, 3.5 mmol), tetrakis(triphenylphosphine)palladium (0) (131 mg, 0.11 mmol), and sodium carbonate (0.75 g, 7.1 mmol) were placed in a tube under nitrogen. Water (3 mL), ethanol (3 mL) and tetrahydrofuran (12 mL) were added. The mixture was then heated at 70 °C and stirred under nitrogen for 24 h. The mixture was then evaporated under vacuum and the residue from evaporation was partitioned between dilute aqueous sodium hydroxide and chloroform, the layers were separated, and the aqueous layer was further extracted with chloroform. The chloroform extract was dried (magnesium

sulfate), filtered, and evaporated. The residue was purified by reverse phase HPLC on a Waters Novapak-HR C₁₈ Column using a gradient of 0-70% acetonitrile / water (each solvent containing 0.1% trifluoroacetic acid as a buffer) as the eluant. The product-containing fractions were evaporated, then the residue was dissolved in methanol. Excess concentrated hydrochloric acid was added, and the solution was evaporated to give the dihydrochloride salt of the title compound (489 mg) as a colourless solid; m.p. 223-225 °C (decomp.); m/z 283 (100%, MH⁺).

Example 1


(2'R)-5'-(Benzofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]




Prepared by a method analogous to that described for the preparation of (2'R)-5'-(furan-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] in Preparation 1 from (2'R)-5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and benzofuran-2-boronic acid. The compound was purified by flash chromatography using a gradient of ammoniated methanol in chloroform and obtained as a pale solid; m/z 333 (100%, MH⁺).

Example 2


(2'R)-5'-(2-Bromofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]



(2'R)-5'-(Furan-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (102 mg, 0.37 mmol), was stirred with bromine (65 mg, 0.41 mmol) in DMF (3 ml) at room temperature for 1h. Vacuum was applied, and the mixture was stirred for a further 30 min. The reaction mixture was diluted with chloroform, and washed with aqueous sodium hydroxide, then the organic layer was dried, filtered and evaporated. The compound was purified by flash chromatography using a gradient of ammoniated methanol in chloroform to give the title compound (28 mg) as a pale solid; m/z 361, 363 (MH⁺).

Example 3(2'R)-5'-(5-Methylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

Prepared by a method analogous to that described for the preparation of (2'R)-5'-(furan-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] in Preparation 1 from (2'R)-5'-bromo-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and 5-methylfuran-2-boronic acid. The title compound was obtained as a colourless solid; m/e 297 (MH^+).

Example 4(2'R)-5'-(5-Fluorofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]**(a) 5-Fluoro-2-tri-*n*-butylstannylfuran**


5-Bromo-2-furoic acid (300 mg, 1.57 mmol) and sodium bicarbonate (316 mg, 3.76 mmol) was stirred in 3.5 mL of pentane/water (2:5) at room temperature for 5 minutes. 1-Chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane bis-(tetrafluoroborate ("Selectfluor®")) (668 mg, 1.88 mmol) was added, and the mixture was stirred for another hour at room temperature. The pentane layer containing 5-bromo-2-fluorofuran was separated from the mixture, dried ($MgSO_4$), and used for next step directly. The pentane solution of 5-bromo-2-fluorofuran was diluted with 3 mL of anhydrous ether, and cooled to $-78^\circ C$ under nitrogen. *n*-Butyllithium (1.6M, 0.25 mL, 0.39 mmol) was added, and the solution was stirred at $-78^\circ C$ for 10 minutes. Tri-*n*-butylstannyl chloride (127 mg, 0.39 mmol) then was added, and the solution was allowed to warm to room temperature, and stirred for another 20 minutes. The mixture was quenched and washed with 1N sodium hydroxide, then the organic layer was separated, dried through $MgSO_4$, and filtered, and then the solvent was evaporated to give the sub-title compound (155 mg) as a brown oil which was used without further purification for the next step.

(b) (2'R)-5'-(5-Fluorofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

(2'R)-5'-Bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (80 mg, 0.27 mmol), 2-tri-*n*-butylstannyl-5-fluorofuran (102 mg, 0.27 mmol) and tetrakis(triphenylphosphine)palladium (0) (32 mg, 0.027 mmol) were mixed with 1 mL of toluene and sealed under nitrogen. The mixture was stirred and heated at 120 °C under nitrogen for 2 h. The mixture was then allowed to cool, and filtered through diatomaceous earth. The filtrate was diluted with chloroform, washed with saturated sodium bicarbonate, dried through MgSO₄, filtered, and then the solvent was evaporated. The compound was purified by flash chromatography using a gradient of ammoniated methanol in chloroform followed by reverse phase HPLC on a Waters Novapak-HR C₁₈ Column using a gradient of 0 - 65% acetonitrile/water (each solvent containing 0.1% trifluoroacetic acid as a buffer) as the eluant. The product-containing collections were evaporated. The residue was dissolved in methanol, then excess 1N hydrochloric acid was added, and the solvent was evaporated to give the dihydrochloride salt of the title compound (40 mg) as a colourless solid; m/e 301 (MH⁺).

Example 5

(2'R)-5'-(5-Methylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]



(a) (2'R)-5'-Trimethylstannyl-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

(2'R)-5'-Bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (690 mg, 2.34 mmol), hexamethylditin (1.225 g, 0.27 mmol) and tetrakis(triphenylphosphine)palladium (0) (266 mg, 0.027 mmol) were mixed with 10 mL of toluene and sealed under nitrogen. The mixture was stirred and heated at 120 °C under nitrogen for 4 h. The mixture was then allowed to cool and filtered through diatomaceous earth. The filtrate was diluted with chloroform, washed with saturated sodium bicarbonate, dried through MgSO₄, filtered, and then the solvent was evaporated. Purification by flash chromatography using a gradient of ammoniated methanol in chloroform gave the sub-title compound as a pale solid (780 mg); m/e 377 379 381 (MH⁺). The compound was used in step (c) without further purification.

(b) 4-Bromo-2-methylfuran


4-Bromo-2-furaldehyde (220 mg, 1.26 mmol) and hydrazine (161 mg, 5.03 mmol) were stirred in 3 mL of anhydrous ether at room temperature for 5 minutes. Then calcium chloride (168 mg, 1.51 mmol) was added, and the mixture was stirred for 1h. The mixture was filtered, and the filtrate was evaporated. The residue was dissolved in 2 mL of anhydrous ethanol, and sodium ethoxide (685 mg, 10.1 mmol) was added. The reaction was heated at 90 °C for 2 h. The mixture was diluted with a large amount of water, and extracted with pentane. The organic layer was washed with water and brine, and dried through MgSO₄. Because the product was very volatile, the product-containing solution was used for step (c) without evaporation of further purification; m/e 160, 162 (M⁺).

(c) (2'R)-5'-(5-Methylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

(2'R)-5'-Bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (125 mg, 0.23 mmol), 4-bromo-2-methyl-furan (1.2 mL of the solution from step (b) above) and tetrakis(triphenylphosphine)palladium (0) (23mg, 0.02 mmol) were mixed with 2 mL of toluene and sealed under nitrogen. The mixture was stirred and heated at 120 °C for 2 h under nitrogen. The mixture was filtered through diatomaceous earth. The filtrate was diluted with chloroform, washed with saturated sodium bicarbonate, dried through MgSO₄, filtered, and then the solvent was evaporated. The compound was purified by flash chromatography followed by reverse phase HPLC on a Waters Novapak-HR C₁₈ Column using a gradient of 0 - 65% acetonitrile/water (each solvent containing 0.1% trifluoroacetic acid as a buffer) as the eluant. The product-containing collections were evaporated. The residue was dissolved in methanol, then excess 1N hydrochloric acid was added, and the solvent was evaporated to give the dihydrochloride salt of the title compound (3 mg) as a colourless solid; m/e 297 (MH⁺).

Example 6

(2'R)-4-{Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carboxaldehyde




Prepared by a method analogous to that described for the preparation of Example 5 from (2'R)-5'-trimethylstannylspiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and 4-

bromo-2-furaldehyde and purified by flash chromatography using a gradient of ammoniated methanol in chloroform the title compound as a brown oil; m/e 311 (MH⁺).

Example 7


(2'R)-5'-(5-Hydroxymethylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]



(2'R)-4-{Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl} furan-2-carboxaldehyde (180 mg, 0.41 mmol), and CeCl₃ (181 mg, 0.49 mmol) were stirred in 2 mL of ethanol at room temperature for 30 min. The solution was cooled to 0 °C and sodium borohydride (62 mg, 1.64 mmol) was added, and stirring was continued at 0 °C for 2 h. The mixture was diluted with a large amount of chloroform, and then washed with saturated sodium bicarbonate, dried through MgSO₄, filtered, and then the solvent was evaporated. After flash chromatography using a gradient of ammoniated methanol in chloroform the title compound (64 mg) was obtained as a pale solid; m/e 313 (MH⁺).

Example 8

(2'R)-4-{Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl} furan-2-carbonitrile



(a) 4-Bromofuran-2-carbonitrile

4-Bromofuran-2-carboxaldehyde (3.70 g, 21.15 mmol) was dissolved in 150 mL of methanol / dichloromethane (1:4 by volume). Pyridine (3.4 mL, 42.30 mmol) and hydroxylamine hydrochloride (1.50 g, 21.15 mmol) were added sequentially. The mixture was stirred at room temperature. After 2 h, the solvent was evaporated from the reaction mixture. The residue was dissolved in dichloromethane (180 mL), and pyridine (3.4 mL, 42.30 mmol) was added. The mixture was cooled to 0 °C, then phenylphosphonic dichloride (8.46 g, 42.30 mmol) was added. The reaction mixture was then allowed to warm to room temperature and stirred overnight. The reaction mixture was then washed with saturated sodium bicarbonate, water, and brine. The organic layer was dried through MgSO₄, and then the solvent was evaporated.

Flash chromatography using a gradient of ammoniated methanol in chloroform as the eluant gave the sub-title compound (2.85 g) as a pale-yellow solid.

(b) 4-Tri-*n*-butylstannylfuran-2-carbonitrile

n-Butyllithium (1.6M, 3.7 mL, 5.93 mmol) was added to a solution of 4-bromofuran-2-carbonitrile (850 mg, 4.94 mmol) in anhydrous ether (15 mL) stirred at -78°C under nitrogen. After 10 min, tri-*n*-butylstannyl chloride (1.61 g, 4.94 mmol) was added, then the reaction mixture was allowed to warm to room temperature, and stirred for another 1 h. The mixture was quenched, and washed with 1N sodium hydroxide, dried through MgSO_4 , and then the solvent was evaporated to give a brown oily residue. Purification by flash chromatography using a gradient of ammoniated methanol in chloroform gave the sub-title compound as a yellow oil (1.0 g).

(c) (2'R)-4-{Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl]}furan-2-carbonitrile

Method A


Prepared by a method analogous to that described for the preparation of Example 5 from (2'R)-5'-trimethylstannyl-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and 4-bromofuran-2-carbonitrile. The title compound was obtained as a colourless solid; m/e 308 (MH^+).

Method B

Prepared by a method analog to that described for the preparation of Example 4 from (2'R)-5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and 4-tri-*n*-butylstannylfuran-2-carbonitrile.

Example 9

(2'R)-5-{Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl]}furan-2-carbonitrile



(a) 5-Bromofuran-2-carbonitrile


Prepared by a method analogous to that described above for the preparation of 4-bromofuran-2-carbonitrile from 5-bromofuran-2-carboxaldehyde and obtained as a brown oil.

(b) (2'R)-5-{Spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carbonitrile

Prepared by a method analog to that described for the preparation of Example 5 from (2'R)-5'-trimethylstannyl-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and 5-bromofuran-2-carbonitrile. The title compound was obtained as a colourless solid; m/e 308.3 (MH⁺).

Example 10

(2'R)-5'-(Benzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]



(a) 3-Tri-*n*-butylstannylbenzofuran

A solution of bromine (4.49 g, 28.09 mmol) in chloroform (5 mL), was added slowly to a stirred mixture of benzofuran (1.58 g, 13.38 mmol) and potassium acetate (2.69 g, 27.42 mmol) in chloroform (20 mL) at room temperature. After the addition was complete, the reaction mixture was warmed to 50 °C and stirred at this temperature for 5 h. The solution was then allowed to cool, and washed with 5% NaHSO₃, then brine, then dried through MgSO₄, filtered and evaporated to give *trans*-2,3-dihydro-2,3-dibromo-benzofuran as a pale-yellow solid (2.88 g). The pale-yellow solid (2.18 g, 7.84 mmol) was dissolved in anhydrous ethanol (20 mL) then sodium ethoxide (1.33 g, 19.60 mmol) was added and the resulting mixture was heated to 50 °C and stirred at this temperature for 5 h. The solution was allowed to cool, then brine added, and the solution was extracted with ether. The ether layer was washed with water and brine, dried through MgSO₄, and the solvent was evaporated to give a brown oily residue. Purification by flash chromatography using a gradient of ammoniated methanol in chloroform gave 3-bromo-benzofuran as a light-brown oil (1.50 g). Under nitrogen, the 3-bromobenzofuran (450 mg, 2.28 mmol) was then dissolved in anhydrous ether, (10 mL) and stirred at -78 °C. *n*-Butyllithium (1.6M, 2.3 mL, 3.65 mmol) was added, and stirring was continued at -78 °C. After 15 min, tri-*n*-butylstannyl chloride (668 mg, 2.05 mmol) was added, then the solution was allowed to warm to room temperature, and stirring was continued for another 1 h. The mixture was quenched, and washed with 1N sodium hydroxide, dried through MgSO₄, and then the solvent was evaporated to give a brown oily


residue. Purification by flash chromatography using a gradient of ammoniated methanol in chloroform as the eluant gave the sub-title compound as a yellow oil (570 mg).

(b) (2'R)-5'-(Benzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

Prepared by a method analogous to that described for the preparation of Example 4 from (2'R)-5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and 3-tri-*n*-butylstannylbenzofuran. The title compound was obtained as a colourless solid; *m/e* 333 (MH^+).

Example 11

(2'R)-5'-(2-Fluorobenzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]



(a) 2-Fluoro-3-triethylstannyl-benzofuran

Chloromethyl-4-fluoro-1,4-diazobicyclo[2.2.2]octane bis-(tetrafluoroborate ("Selectfluor®")) (13.11 g, 37.01 mmol) was added to a mixture of benzofuran-2-carboxylic acid (5.0 g, 30.84 mmol) and sodium bicarbonate (6.22 g, 74.0 mmol) stirred in 70 mL of pentane / water (2:5 by volume) at room temperature. After 1 hour at the pentane layer containing 2-

fluorobenzofuran was separated from the mixture, and the water layer was extracted with pentane. The combined organic extract was dried through $MgSO_4$, and then the solvent was

evaporated to give 2-fluorobenzofuran (1.70 g) as a yellow oil. The 2-fluorobenzofuran (850 mg, 6.24 mmol) and potassium acetate (1.29 g, 13.11 mL) were stirred in of chloroform (3.5 mL) at room temperature, and a solution of bromine (2.05 g, 12.80 mmol) in of chloroform (1 mL), and added slowly into the reaction mixture. After stirring for 1 h at room temperature,

the mixture was washed with 5% $NaHSO_3$ then brine, dried through $MgSO_4$, and the solvent was evaporated to give *trans*-2-fluoro-3-hydro-2,3-dibromo-benzofuran as a light-brown oil

(1.70 g). *trans*-2-Fluoro-3-hydro-2,3-dibromo-benzofuran (1.66 g, 5.62 mmol) was dissolved in anhydrous ethanol (11 mL), and sodium ethoxide (420 mg, 6.18 mmol) was added. The mixture was stirred at RT for 5 min then brine was added, and the solution was extracted with pentane. The pentane layer was washed with water and with brine, dried through $MgSO_4$, and

then the solvent was evaporated to give 3-bromo-2-fluorobenzofuran as a light-brown oil (950


mg). Under nitrogen, 3-bromo-2-fluorobenzofuran (465 mg, 2.16 mmol) was dissolved in anhydrous ether (5 mL), and stirred at -78°C under nitrogen. *n*-Butyllithium (1.6M, 1.50 mL, 2.38 mmol) was added followed after 5 min by triethylstannyl bromide (680 mg, 2.38 mmol). The mixture was then allowed to warm to room temperature and stirring was continued for a further 1 h. The mixture was quenched, and washed with 1N sodium hydroxide, dried through MgSO_4 , and then the solvent was evaporated to give the sub-title compound as a brown oil (370 mg), which was used directly without further purification for the next step.

(b) (2'R)-5'-(2-Fluorobenzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

Prepared by a method analogous to that described for the preparation of Example 4 from (2'R)-5'-bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] and 2-fluoro-3-triethylstannylbenzofuran. The title compound was obtained as a colourless solid; m/e 351 (MH^+).

CLAIMS

1. A compound having the formula:



I

and pharmaceutically-acceptable salts thereof, wherein

Ar is selected from a 2-, or 3-linked furyl, benzofuryl or isobenzofuryl; substituted with 1, 2 or 3 substitutents, or, when a benzofuryl or isobenzofuryl with 0, 1, 2, or 3 substituents, independently selected at each occurrence from C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ halogenated alkyl, C₁₋₄ oxygenated alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, halogen, -CO₂R¹, -C(O)R¹, -CN, -NO₂, -(CH₂)_nNR¹R²;

n is 0, 1, or 2;

R¹ and R² are independently selected at each occurrence from hydrogen or C₁₋₄alkyl;

R is a substituent selected from hydrogen, C₁₋₄alkyl, C₁₋₄ halogenated alkyl, C₁₋₄ oxygenated alkyl, or halogen.

2. A compound according to Claim 1 or a pharmaceutically-acceptable salt thereof, wherein:

Ar is a 2-, or 3-linked furyl ring bearing a single substituent and said substituent is selected from methyl, ethyl, or halogen, and

R is hydrogen.

3. A compound according to Claim 1, selected from:

(2'R)-5'-(benzofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(2-bromofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-methylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-fluorofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-methylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-4-{spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carboxaldehyde;

(2'R)-5'-(5-hydroxymethylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-4-{spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carbonitrile;

5 (2'R)-5-{spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridin-5'-yl}furan-2-carbonitrile;

(2'R)-5'-(benzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(2-fluorobenzofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

10 (2'R)-5'-(5-fluorofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-chlorofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-bromofuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-trifluoromethylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

15 (2'R)-5'-(5-aminomethylfuran-3-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-chlorofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-bromofuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(5-trifluoromethylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

20 (2'R)-5'-(5-aminomethylfuran-2-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine];

(2'R)-5'-(2,3-dimethylfuran-4-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine], or

25 (2'R)-5'-(2,3-dimethylfuran-5-yl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine].

4. A pharmaceutical composition comprising a compound according to Claim 1, and a pharmaceutically-acceptable diluent or carrier.

5. The pharmaceutical composition according to Claim 4, for use in the treatment of prophylaxis of human diseases or conditions in which activation of the α_7 nicotinic receptor is beneficial.

6. The pharmaceutical composition according to Claim 4, for use in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

7. The pharmaceutical composition according to Claim 4, for use in the treatment or prophylaxis of Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative colitis.

8. Use of a compound according to Claim 1, in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which activation of the α_7 nicotinic receptor is beneficial.

9. Use of a compound according to Claim 1, in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

10. The use according to Claim 9, wherein the condition or disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder.

11. The use according to Claim 9, wherein the disorder is anxiety, schizophrenia, or mania or manic depression.

12. The use as claimed in claim 9, wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.

13. Use of a compound according to Claim 1 in the manufacture of a medicament for the treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, craving, pain, and for ulcerative
5 colitis.

14. A method of treatment or prophylaxis of human diseases or conditions in which activation of the α_7 nicotinic receptor is beneficial which comprises administering a therapeutically effective amount of a compound according to Claim 1.

10 15. A method of treatment or prophylaxis of psychotic disorders or intellectual impairment disorders, which comprises administering a therapeutically effective amount of a compound according to Claim 1.

15 16. The method according to Claim 15, wherein said psychotic disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder Parkinson's disease, Huntington's disease, Tourette's syndrome, a neurodegenerative disorder in which there is loss of cholinergic synapses anxiety, schizophrenia or mania or manic depression.


20 17. A method of treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction, craving, pain, and for ulcerative colitis, which comprises administering a therapeutically effective amount of a compound according to Claim 1.

25 18. A compound according to Claim 1, wherein one or more of the atoms is a radioisotope of the element.

19. A compound according to Claim 18, wherein the radioisotope is tritium.

30 20. The use of a compound according to Claim 19, in a screen for the discovery of novel medicinal compounds which bind to and modulate the activity, *via* agonism, partial agonism, or antagonism, of the α_7 nicotinic acetylcholine receptor.

21. A compound of formula IV:



wherein:

5 M is $B(OH)_2$, $B(OR^3)_2$ or SnR^3_3 ;

R is a substituent selected from hydrogen, C_{1-4} alkyl, C_{1-4} halogenated alkyl, C_{1-4} oxygenated alkyl, or halogen, and

R^3 is a C_1 - C_6 alkyl group.

10 22. A compound according to Claim 21 which is (2'R)-5'-trimethylstannyl-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine].

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00613

A. CLASSIFICATION OF SUBJECT MATTER		
IPC7: C07D 491/22, A61K 31/438, A61K 31/439, A61P 25/00 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC7: C07D, A61K, A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
SE,DK,FI,NO classes as above		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9903859 A1 (ASTRA AKTIEBOLAG), 28 January 1999 (28.01.99) --	1-22
A	WO 0042044 A1 (ASTRAZENECA AB), 20 July 2000 (20.07.00) --	1-17
P,A	US 2003018042 A1 (PHILLIPS EIFION), 23 January 2003 (23.01.03) --	1-17
P,A	WO 02096912 A1 (ASTRAZENECA AB), 5 December 2002 (05.12.02) --	1-17
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
15 July 2003		15 -07- 2003
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer Eva Johansson/EÖ Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 03/00613

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 0045846 A1 (SANOFI-SYNTHELABO), 10 August 2000 (10.08.00) -- -----	1-17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE03/00613**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14-17
because they relate to subject matter not required to be searched by this Authority, namely:
see next sheet
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Claims 14-17 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

INTERNATIONAL SEARCH REPORT
Information on patent family members

29/06/03

International application No.

PCT/SE 03/00613

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9903859	A1	28/01/99	AT	225792 T	15/10/02
				AU	739022 B	04/10/01
				AU	8367998 A	10/02/99
				BR	9810924 A	15/08/00
				CN	1270592 T	18/10/00
				DE	69808631 D,T	12/06/03
				EE	200000031 A	16/10/00
				EP	0996622 A,B	03/05/00
				SE	0996622 T3	
				EP	1213291 A	12/06/02
				ES	2185185 T	16/04/03
				HU	0003844 A	30/07/01
				IL	134086 D	00/00/00
				JP	2001510194 T	31/07/01
				NO	20000226 A	14/03/00
				NZ	502298 A	01/02/02
				PL	338259 A	09/10/00
				PT	996622 T	31/01/03
				SE	9702746 D	00/00/00
				SI	996622 T	00/00/00
				SK	183599 A	14/08/00
				TR	200000129 T	00/00/00
				US	6110914 A	29/08/00
				US	6369224 B	09/04/02
				ZA	9805995 A	03/08/99
				SE	9800977 D	00/00/00
				WO	9961990 A	02/12/99

WO	0042044	A1	20/07/00	AT	240960 T	15/06/03
				AU	2334300 A	01/08/00
				BR	9916906 A	30/10/01
				CA	2359990 A	20/07/00
				CN	1337964 T	27/02/02
				CZ	20012554 A	16/01/02
				DE	69902753 D,T	15/05/03
				DE	69908185 D	00/00/00
				EE	200100370 A	15/10/02
				EP	1054754 A,B	29/11/00
				EP	1147114 A,B	24/10/01
				HU	0200513 A	29/06/02
				IL	144266 D	00/00/00
				JP	2002502715 T	29/01/02
				JP	2002534525 T	15/10/02
				NO	20013478 A	14/09/01
				SE	9900100 D	00/00/00
				SK	9932001 A	04/04/02
				TR	200102042 T	00/00/00
				US	6527060 B	04/03/03

US	2003018042	A1	23/01/03	US	6569865 B	27/05/03

WO	02096912	A1	05/12/02	NONE		

INTERNATIONAL SEARCH REPORT

Information on patent family members

29/06/03

International application No.

PCT/SE 03/00613

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	0045846	A1	10/08/00	AU	2298800 A	25/08/00
				AU	3714299 A	06/12/99
				BR	9910436 A	21/05/02
				CA	2332435 A	25/11/99
				CA	2361437 A	10/08/00
				EP	1077886 A	28/02/01
				EP	1150715 A	07/11/01
				FR	2788982 A,B	04/08/00
				HU	0201279 A	28/09/02
				JP	2002515385 T	28/05/02
				JP	2002536342 T	29/10/02
